179 - Clinical Controversies

Friday, October 18, 2024

3:15 PM – 4:30 PM US PT

Location: Concourse 152

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Debate Style Moderator(s)

Susan Casey, MD FIDSA FACP (she/her/hers)

VP/Chief Quality and Safety
University of Maryland Medical Center
Baltimore , MD, United States

Slides
Alice Kim, MD, MBA

President and CEO
ID CARE
Morristown, NJ, United States

Faculty(s)

Kelly Reveles, PharmD, PhD, BCIDP (she/her/hers)

Associate Professor
The University of Texas at Austin
San Antonio, TX, United States
ED

Erik Dubberke, MD, MSPH

Professor of Medicine
Washington University School of Medicine
Gregory Schrank, MD MPH (he/him/his)

Assistant Professor of Medicine
University of Maryland School of Medicine
Baltimore, Maryland, United States
Theresa Madaline, MD, FIDSA, FACP, CPHQ (she/her/hers)

Associate Chief Quality Officer
NewYork-Presbyterian/Columbia University

Disclosure(s):

Susan Casey: No financial relationships to disclose

Alice I. Kim, MD, MBA: No financial relationships to disclose

Kelly R. Reveles, PharmD, PhD, BCIDP: AstraZeneca: Grant/Research Support (Ongoing); Ferring Pharmaceuticals Inc.: Advisor/Consultant (Ongoing), Honoraria (Ongoing)

Erik Dubberke, MD, MSPH: AstraZeneca: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Ferring: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Merck: Advisor/Consultant (Ongoing); Pfizer: Grant/Research Support (Ongoing); Recursion: Advisor/Consultant (Ongoing); Seres Therapeutics: Advisor/Consultant (Ongoing); Theriva Biologics: Grant/Research Support (Ongoing); Vedanta: Grant/Research Support (Ongoing)

Gregory M. Schrank, MD MPH: EnSenSys, LLC: Grant/Research Support (Ongoing)

Theresa Madaline, MD, FIDSA, FACP, CPHQ: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

investigate the evidence for use of fidaxomicin;
explain the use of bezlotuxumab;
describe the implications of hospital onset bacteremia and preventability;
advise decisions on pay for performance measures.

Presentations:

3:15 PM – 3:33 PM US PT

Fidaxomicin isn't necessary with Vancomycin and Bezlotuxumab: Pro
Debate Style Speaker: Kelly R. Reveles, PharmD, PhD, BCIDP (she/her/hers) – The University of Texas at Austin
3:33 PM – 3:51 PM US PT

Fidaxomicin isn't necessary with Vancomycin and Bezlotuxumab: Con
Debate Style Speaker: Erik Dubberke, MD, MSPH – Washington University School of Medicine
3:51 PM – 4:09 PM US PT

Hospital Onset Bacteremia should be used as a pay for performance measure: Pro
Debate Style Speaker: Gregory M. Schrank, MD MPH (he/him/his) – University of Maryland School of Medicine
4:09 PM – 4:30 PM US PT

Hospital Onset Bacteremia should be used as a pay for performance measure: Con
Debate Style Speaker: Theresa Madaline, MD, FIDSA, FACP, CPHQ (she/her/hers) – NewYork-Presbyterian/Columbia University